A Phase II study of high-dose tamoxifen in patients with hormone- refractory prostate cancer

Raymond Bergan, Eddie Reed, Charles E. Myers, Donna Headlee, Otis Brawley, Hea Kyoung Cho, W. Douglas Figg, Anne Tompkins, W. Marston Linehan, David Kohler, Seth M. Steinberg, Mikhail V. Blagosklonny

Research output: Contribution to journalArticle

84 Citations (Scopus)

Abstract

Micromolar concentrations of tamoxifen inhibit the activity of protein kinase C and were recently shown to inhibit prostate cancer cell growth in preclinical studies. Because micromolar concentrations can be attained with high-dose therapy, the clinical activity of high-dose tamoxifen was evaluated in patients with metastatic adenocarcinoma of the prostate. Between December 1993 and February 1997, 30 patients with hormone-refractory metastatic adenocarcinoma of the prostate were continuously administered tamoxifen at 160 mg/m2/day. Therapy was continued until disease progression. All study patients had failed prior treatment with combined androgen blockade, had castrate levels of testosterone, and were heavily pretreated, having received a median of three prior regimens. The average steady-state plasma concentration of tamoxifen was 2.96 ± 1.32 μM (mean ± SD). Grade 3 neurotoxicity was observed in 29% of patients and was rapidly reversible and readily managed with dose modification. Otherwise, grade 3 toxicities were rare. One partial response (80% decline in prostate-specific antigen) was observed (3.3%), whereas disease stabilization was observed in six patients (20%), for a combined partial response/stable disease response rate of 23%. Median time to progression was 2.1 months, and median survival time was 10.5 months. High-dose tamoxifen therapy was well tolerated and associated with micromolar concentrations of tamoxifen in human plasma, and it demonstrated activity, albeit limited, in a heavily pretreated patient cohort with hormone-refractory prostate cancer. These findings suggest that further investigation of the role of protein kinase C modulation in prostate cancer is warranted.

Original languageEnglish (US)
Pages (from-to)2366-2373
Number of pages8
JournalClinical Cancer Research
Volume5
Issue number9
StatePublished - Sep 1999
Externally publishedYes

Fingerprint

Tamoxifen
Prostatic Neoplasms
Hormones
Protein Kinase C
Prostate
Adenocarcinoma
Therapeutics
Prostate-Specific Antigen
Androgens
Disease Progression
Testosterone
Survival
Growth

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Bergan, R., Reed, E., Myers, C. E., Headlee, D., Brawley, O., Cho, H. K., ... Blagosklonny, M. V. (1999). A Phase II study of high-dose tamoxifen in patients with hormone- refractory prostate cancer. Clinical Cancer Research, 5(9), 2366-2373.

A Phase II study of high-dose tamoxifen in patients with hormone- refractory prostate cancer. / Bergan, Raymond; Reed, Eddie; Myers, Charles E.; Headlee, Donna; Brawley, Otis; Cho, Hea Kyoung; Figg, W. Douglas; Tompkins, Anne; Linehan, W. Marston; Kohler, David; Steinberg, Seth M.; Blagosklonny, Mikhail V.

In: Clinical Cancer Research, Vol. 5, No. 9, 09.1999, p. 2366-2373.

Research output: Contribution to journalArticle

Bergan, R, Reed, E, Myers, CE, Headlee, D, Brawley, O, Cho, HK, Figg, WD, Tompkins, A, Linehan, WM, Kohler, D, Steinberg, SM & Blagosklonny, MV 1999, 'A Phase II study of high-dose tamoxifen in patients with hormone- refractory prostate cancer', Clinical Cancer Research, vol. 5, no. 9, pp. 2366-2373.
Bergan R, Reed E, Myers CE, Headlee D, Brawley O, Cho HK et al. A Phase II study of high-dose tamoxifen in patients with hormone- refractory prostate cancer. Clinical Cancer Research. 1999 Sep;5(9):2366-2373.
Bergan, Raymond ; Reed, Eddie ; Myers, Charles E. ; Headlee, Donna ; Brawley, Otis ; Cho, Hea Kyoung ; Figg, W. Douglas ; Tompkins, Anne ; Linehan, W. Marston ; Kohler, David ; Steinberg, Seth M. ; Blagosklonny, Mikhail V. / A Phase II study of high-dose tamoxifen in patients with hormone- refractory prostate cancer. In: Clinical Cancer Research. 1999 ; Vol. 5, No. 9. pp. 2366-2373.
@article{2c3d91e3502649ec99d0227d9406dcbb,
title = "A Phase II study of high-dose tamoxifen in patients with hormone- refractory prostate cancer",
abstract = "Micromolar concentrations of tamoxifen inhibit the activity of protein kinase C and were recently shown to inhibit prostate cancer cell growth in preclinical studies. Because micromolar concentrations can be attained with high-dose therapy, the clinical activity of high-dose tamoxifen was evaluated in patients with metastatic adenocarcinoma of the prostate. Between December 1993 and February 1997, 30 patients with hormone-refractory metastatic adenocarcinoma of the prostate were continuously administered tamoxifen at 160 mg/m2/day. Therapy was continued until disease progression. All study patients had failed prior treatment with combined androgen blockade, had castrate levels of testosterone, and were heavily pretreated, having received a median of three prior regimens. The average steady-state plasma concentration of tamoxifen was 2.96 ± 1.32 μM (mean ± SD). Grade 3 neurotoxicity was observed in 29{\%} of patients and was rapidly reversible and readily managed with dose modification. Otherwise, grade 3 toxicities were rare. One partial response (80{\%} decline in prostate-specific antigen) was observed (3.3{\%}), whereas disease stabilization was observed in six patients (20{\%}), for a combined partial response/stable disease response rate of 23{\%}. Median time to progression was 2.1 months, and median survival time was 10.5 months. High-dose tamoxifen therapy was well tolerated and associated with micromolar concentrations of tamoxifen in human plasma, and it demonstrated activity, albeit limited, in a heavily pretreated patient cohort with hormone-refractory prostate cancer. These findings suggest that further investigation of the role of protein kinase C modulation in prostate cancer is warranted.",
author = "Raymond Bergan and Eddie Reed and Myers, {Charles E.} and Donna Headlee and Otis Brawley and Cho, {Hea Kyoung} and Figg, {W. Douglas} and Anne Tompkins and Linehan, {W. Marston} and David Kohler and Steinberg, {Seth M.} and Blagosklonny, {Mikhail V.}",
year = "1999",
month = "9",
language = "English (US)",
volume = "5",
pages = "2366--2373",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "9",

}

TY - JOUR

T1 - A Phase II study of high-dose tamoxifen in patients with hormone- refractory prostate cancer

AU - Bergan, Raymond

AU - Reed, Eddie

AU - Myers, Charles E.

AU - Headlee, Donna

AU - Brawley, Otis

AU - Cho, Hea Kyoung

AU - Figg, W. Douglas

AU - Tompkins, Anne

AU - Linehan, W. Marston

AU - Kohler, David

AU - Steinberg, Seth M.

AU - Blagosklonny, Mikhail V.

PY - 1999/9

Y1 - 1999/9

N2 - Micromolar concentrations of tamoxifen inhibit the activity of protein kinase C and were recently shown to inhibit prostate cancer cell growth in preclinical studies. Because micromolar concentrations can be attained with high-dose therapy, the clinical activity of high-dose tamoxifen was evaluated in patients with metastatic adenocarcinoma of the prostate. Between December 1993 and February 1997, 30 patients with hormone-refractory metastatic adenocarcinoma of the prostate were continuously administered tamoxifen at 160 mg/m2/day. Therapy was continued until disease progression. All study patients had failed prior treatment with combined androgen blockade, had castrate levels of testosterone, and were heavily pretreated, having received a median of three prior regimens. The average steady-state plasma concentration of tamoxifen was 2.96 ± 1.32 μM (mean ± SD). Grade 3 neurotoxicity was observed in 29% of patients and was rapidly reversible and readily managed with dose modification. Otherwise, grade 3 toxicities were rare. One partial response (80% decline in prostate-specific antigen) was observed (3.3%), whereas disease stabilization was observed in six patients (20%), for a combined partial response/stable disease response rate of 23%. Median time to progression was 2.1 months, and median survival time was 10.5 months. High-dose tamoxifen therapy was well tolerated and associated with micromolar concentrations of tamoxifen in human plasma, and it demonstrated activity, albeit limited, in a heavily pretreated patient cohort with hormone-refractory prostate cancer. These findings suggest that further investigation of the role of protein kinase C modulation in prostate cancer is warranted.

AB - Micromolar concentrations of tamoxifen inhibit the activity of protein kinase C and were recently shown to inhibit prostate cancer cell growth in preclinical studies. Because micromolar concentrations can be attained with high-dose therapy, the clinical activity of high-dose tamoxifen was evaluated in patients with metastatic adenocarcinoma of the prostate. Between December 1993 and February 1997, 30 patients with hormone-refractory metastatic adenocarcinoma of the prostate were continuously administered tamoxifen at 160 mg/m2/day. Therapy was continued until disease progression. All study patients had failed prior treatment with combined androgen blockade, had castrate levels of testosterone, and were heavily pretreated, having received a median of three prior regimens. The average steady-state plasma concentration of tamoxifen was 2.96 ± 1.32 μM (mean ± SD). Grade 3 neurotoxicity was observed in 29% of patients and was rapidly reversible and readily managed with dose modification. Otherwise, grade 3 toxicities were rare. One partial response (80% decline in prostate-specific antigen) was observed (3.3%), whereas disease stabilization was observed in six patients (20%), for a combined partial response/stable disease response rate of 23%. Median time to progression was 2.1 months, and median survival time was 10.5 months. High-dose tamoxifen therapy was well tolerated and associated with micromolar concentrations of tamoxifen in human plasma, and it demonstrated activity, albeit limited, in a heavily pretreated patient cohort with hormone-refractory prostate cancer. These findings suggest that further investigation of the role of protein kinase C modulation in prostate cancer is warranted.

UR - http://www.scopus.com/inward/record.url?scp=0032862225&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032862225&partnerID=8YFLogxK

M3 - Article

C2 - 10499606

AN - SCOPUS:0032862225

VL - 5

SP - 2366

EP - 2373

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 9

ER -